Get the (MYL) Report Here
Trade with Jim Cramer 14 Days FREE
The health sector is one the less-beaten-down areas amid market weakness.
Here are two generic-drug companies that should hold up well, regardless of the current uncertainty.
There's no reason to read much into it.
The generic drugmaker may be preparing to break from a key short-term channel pattern.
Secular trends appear likely to favor Mylan and Teva Pharmaceuticals.
Break in! Morgan Stanley (MS) is defending Mylan (MYL) now.
These two pharmaceuticals are standouts as the sector outperforms today.
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login